Post-Conference Perspectives: Understanding HER2-Low Breast Cancer - Episode 3

Treating HER2-low Breast Cancer With Novel Antibody Drug Conjugates

,

Experts take a look at clinical data behind novel antibody drug conjugates and consider how they may impact the management of HER2-low breast cancer.

EP. 1: Current Landscape of HER2 Testing in Breast Cancer
EP. 2: Strategies in Identifying and Stratifying HER2 Status in Breast Cancer
Now Viewing
EP. 3: Treating HER2-low Breast Cancer With Novel Antibody Drug Conjugates
EP. 4: HER2-low Breast Cancer: Practical Applications of ADC Therapy

Related Content:

Post-Conference Perspectives: Understanding HER2-Low Breast CancerBreast Cancer
Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer
Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast Cancer
STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers